GlassScriptPhysician profile
Zhu-Ping Zhou
NPI 1871655944
$32,936.76
in general payments reported to CMS, 2019-2025
51 companies · $6,193 in 2025
The $6,193 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,947 · 2020: $2,862 · 2021: $4,745 · 2022: $5,348 · 2023: $5,250 · 2024: $5,591 · 2025: $6,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $53.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,981.00 |
| Education | $53.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,137.15 | 2019-2025 | |
| Abbvie INC. | $3,132.06 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $3,056.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $1,512.39 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $1,443.39 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,419.72 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $1,353.21 | 2019-2023 | |
| Amgen INC. | $1,280.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $1,170.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ardelyx, INC. | $1,102.55 | 2022-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $1,085.99 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,048.03 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,032.16 | 2022-2025 | |
| Radius Health, INC. | $1,001.11 | 2019-2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $983.14 | 2019-2025 | Trintellix |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhu-Ping Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.